Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
First patient recruited for clinical study in breast cancer patients
October 20th, 2005
NeuTec Pharma plc announced that it has recruited its first patient in a clinical study in breast cancer patients. The phase Ib, pharmacokinetic, multi-center, open label study will evaluate the safety and efficacy of Mycograb administered in combination with Docetaxel in metastatic or recurrent breast cancer patients. Mycograb is a human genetically recombinant antibody (grab) that binds to heat shock protein 90 (hsp90) which has been identified as a tumor marker which appears on the outside of certain cancer cells (as with fungi) and is needed for cancer cell survival. The growth of cancer cells is particularly sensitive to the effects of hsp90's...
Source: Women's Health Weekly (2005-10-20)
|
